Birchview Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Birchview Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.81M	Hold	171,000	–	–	2.17%	12
2025 Q4	$4.57M	Hold	171,000	–	–	2.67%	9
2025 Q3	$3.65M	Sell	171,000 -16,800	-9%	-$397K	2.76%	9
2025 Q2	$4.05M	Sell	187,800 -75,600	-29%	-$1.41M	4.02%	5
2025 Q1	$4.38M	Sell	263,400 -75,000	-22%	-$1.36M	3.8%	3
2024 Q4	$6.21M	Sell	338,400 -62,000	-15%	-$1M	5.05%	3
2024 Q3	$6.16M	Buy	400,400 +150,000	+60%	+$2.5M	5.33%	3
2024 Q2	$4.07M	Hold	250,400	–	–	3.76%	7
2024 Q1	$4.63M	Buy	250,400 +10,000	+4%	+$248K	3.77%	5
2023 Q4	$7.53M	Hold	240,400	–	–	5.89%	4
2023 Q3	$5.01M	Sell	240,400 -9,000	-4%	-$244K	4.26%	5
2023 Q2	$5.97M	Hold	249,400	–	–	4.48%	5
2023 Q1	$4.69M	Hold	249,400	–	–	3.68%	6
2022 Q4	$3.97M	Hold	249,400	–	–	2.8%	9
2022 Q3	$4.08M	Hold	249,400	–	–	2.87%	6
2022 Q2	$3.51M	Buy	249,400 +50,000	+25%	+$933K	2.56%	8
2022 Q1	$4.83M	Hold	199,400	–	–	3.48%	5
2021 Q4	$4.65M	Hold	199,400	–	–	3%	8
2021 Q3	$3.31M	Hold	199,400	–	–	2.25%	10
2021 Q2	$4.86M	Buy	199,400 +22,400	+13%	+$506K	2.91%	6
2021 Q1	$4.57M	Buy	177,000 +75,000	+74%	+$3.3M	2.71%	6
2020 Q4	$5.45M	Hold	102,000	–	–	3.14%	8
2020 Q3	$4.21M	Buy	102,000 +9,000	+10%	+$389K	2.81%	6
2020 Q2	$4.51M	Buy	93,000 +1,000	+1%	+$48K	2.72%	6
2020 Q1	$3.89M	Buy	92,000 +78,000	+557%	+$3.21M	3.45%	5
2019 Q4	$599K	Hold	14,000	–	–	0.44%	31
2019 Q3	$504K	Buy	14,000 +4,000	+40%	+$121K	0.34%	29
2019 Q2	$267K	Buy	+10,000	New	+$255K	0.16%	40

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Birchview Capital's ACAD Position: Q1 2026 in Review

Birchview Capital held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2026 at 171,000 shares worth $3.81M. The position accounts for 2.17% of the portfolio, ranked #12.

Birchview Capital first reported a position in ACAD in Q2 2019 and has held it in 28 quarters since. The position peaked at $7.53M in Q4 2023. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Birchview Capital held 171,000 shares of Acadia Pharmaceuticals worth $3.81M as of Q1 2026.
Birchview Capital left its Acadia Pharmaceuticals share count unchanged in Q1 2026.
Acadia Pharmaceuticals made up 2.17% of Birchview Capital's portfolio in Q1 2026, its #12 holding.
Birchview Capital first reported a position in Acadia Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
Birchview Capital's Acadia Pharmaceuticals position peaked at $7.53M in Q4 2023.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.